0QIU.IL
Novo Nordisk A/S
IOBDKKEQUITY
Healthcare
DELAYED
Last price
296.43
▼ 2.07 (0.70%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
298.84
Prev close
298.50
Day high
300.85
Day low
294.25
Volume
820.71K
Market cap
$1.25T
P/E (TTM)
19.97
52W range
50.24 – 409.90
Day trading desk
Gap from prior close
+0.11%
Prior close 298.50
VWAP
297.95
-0.51% from price
Relative volume
1.24×
Normal
Session range
2.24%
294.25 – 300.85
Position in range
33%
Mid range
ATR (14D)
9.72
3.28% of price
Prior day high
301.08
PDH
Prior day low
295.95
PDL
Bid / ask spread
—
Quote not published
Session volume
1.14M
Avg 919.76K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.07%
+0.3%
1M
-6.99%
-10.7%
3M
+2.02%
-1.1%
6M
-2.14%
-13.2%
YTD
-8.99%
-21.3%
1Y
-18.81%
-38.8%
3Y
-53.59%
-127.8%
5Y
-10.14%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on 0QIU.IL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$1.25T
Enterprise value$3.03T
Revenue (TTM)$201.33B
Gross profit$169.82B
EBITDA$92.89B
Net income$67.24B
EPS (TTM)$14.86
Free cash flow$53.32B
Total cash$36.41B
Total debt$25.70B
Book value / share$20.19
Shares outstanding3.40B
Float3.21B
Short % of float—
Dividend yield1.04%
Beta (5Y)0.21
Valuation & profitability ratios
Trailing P/E19.97
Forward P/E—
PEG ratio—
Price / sales—
Price / book14.70
EV / revenue15.07
EV / EBITDA32.65
Gross margin84.35%
Operating margin43.20%
Profit margin33.40%
Return on equity81.54%
Return on assets21.76%
Debt / equity28.41
Current ratio0.88
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $309.06B | $290.40B | $232.26B | $176.95B | +6.4% |
| Operating revenue | $729.42B | $680.56B | $608.64B | $455.69B | +7.2% |
| Cost of revenue | $58.79B | $44.52B | $35.77B | $28.45B | +32.0% |
| Gross profit | $250.28B | $245.88B | $196.50B | $148.51B | +1.8% |
| Research & development | $52.04B | $48.06B | $32.44B | $24.05B | +8.3% |
| Selling, general & admin | $70.28B | $67.38B | $61.60B | $50.68B | +4.3% |
| Total operating expense | $122.62B | $117.54B | $93.92B | $73.70B | +4.3% |
| Operating income | $127.66B | $128.34B | $102.57B | $74.81B | -0.5% |
| Net interest income | -$3.18B | -$91.00M | $330.00M | -$320.00M | -3,393.4% |
| Pre-tax income | $130.54B | $127.19B | $104.67B | $69.06B | +2.6% |
| Tax provision | $28.11B | $26.20B | $20.99B | $13.54B | +7.3% |
| Net income | $102.43B | $100.99B | $83.68B | $55.52B | +1.4% |
| Net income to common | $102.43B | $100.99B | $83.68B | $55.52B | +1.4% |
| Basic EPS | 23.06 | 22.67 | 18.67 | 12.26 | +1.7% |
| Diluted EPS | 23.03 | 22.63 | 18.62 | 12.22 | +1.8% |
| EBIT | $134.75B | $128.83B | $105.22B | $69.44B | +4.6% |
| EBITDA | $156.73B | $147.94B | $114.63B | $76.80B | +5.9% |
| Basic shares | 4.44B | 4.45B | 4.48B | 4.53B | -0.2% |
| Diluted shares | 4.45B | 4.46B | 4.49B | 4.54B | -0.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $26.46B | $15.65B | $14.39B | $12.65B | +69.0% |
| Cash & short-term investments | $26.96B | $26.31B | $30.23B | $23.57B | +2.5% |
| Accounts receivable | $70.86B | $71.95B | $64.77B | $50.56B | -1.5% |
| Inventory | $49.62B | $40.85B | $31.81B | $24.39B | +21.5% |
| Total current assets | $172.45B | $161.79B | $139.65B | $108.19B | +6.6% |
| Property, plant & equipment | $208.38B | $161.68B | $90.96B | $66.67B | +28.9% |
| Goodwill & intangibles | $130.05B | $110.82B | $60.41B | $50.94B | +17.4% |
| Total assets | $542.90B | $465.63B | $314.49B | $241.26B | +16.6% |
| Total current liabilities | $215.66B | $217.61B | $169.66B | $120.94B | -0.9% |
| Current debt | $10.68B | $11.78B | $5.30B | $480.00M | -9.3% |
| Long-term debt | $111.70B | $84.25B | $15.98B | $20.77B | +32.6% |
| Total debt | $130.96B | $102.79B | $27.01B | $25.78B | +27.4% |
| Total liabilities | $348.86B | $322.14B | $207.93B | $157.77B | +8.3% |
| Retained earnings | $195.30B | $144.45B | $104.84B | $80.59B | +35.2% |
| Shareholder equity | $194.05B | $143.49B | $106.56B | $83.49B | +35.2% |
| Working capital | -$43.21B | -$55.83B | -$30.01B | -$12.75B | +22.6% |
| Net tangible assets | $63.99B | $32.66B | $46.16B | $32.55B | +95.9% |
| Shares issued | 4.46B | 4.46B | 4.51B | 4.56B | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $102.43B | $100.99B | $83.68B | $55.52B | — | +1.4% |
| Depreciation & amortisation | $21.98B | $19.11B | $9.41B | $7.36B | — | +15.0% |
| Stock-based compensation | — | $2.29B | $2.15B | $1.54B | $1.04B | — |
| Change in working capital | $3.74B | $2.59B | $19.71B | -$5.54B | — | +44.3% |
| Operating cash flow | $119.10B | $120.97B | $108.91B | $78.89B | — | -1.5% |
| Capital expenditure | -$90.11B | -$51.31B | -$38.90B | -$14.75B | — | -75.6% |
| Investing cash flow | -$79.16B | -$128.90B | -$43.89B | -$24.92B | — | +38.6% |
| Share buybacks | -$1.39B | -$20.18B | -$29.92B | -$24.09B | — | +93.1% |
| Dividends paid | -$51.76B | -$44.14B | -$31.77B | -$25.30B | — | -17.3% |
| Financing cash flow | -$28.41B | $8.73B | -$63.16B | -$51.80B | — | -425.2% |
| Free cash flow | $28.99B | $69.66B | $70.01B | $64.13B | — | -58.4% |
| End cash position | $26.46B | $15.65B | $14.39B | $12.65B | — | +69.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $78.49B | $96.82B | $79.14B | $74.98B | $76.86B | — | -18.9% |
| Operating revenue | $78.49B | $96.82B | $79.14B | $74.98B | $76.86B | — | -18.9% |
| Cost of revenue | $17.10B | $13.60B | $15.15B | $17.90B | $12.85B | — | +25.8% |
| Gross profit | $61.39B | $83.22B | $64.00B | $57.07B | $64.01B | — | -26.2% |
| Research & development | $17.79B | $10.28B | $14.65B | $15.39B | $11.69B | — | +73.0% |
| Selling, general & admin | $16.31B | $13.22B | $17.44B | $17.88B | $18.85B | — | +23.4% |
| Total operating expense | $34.33B | $23.61B | $32.26B | $33.39B | $30.56B | — | +45.4% |
| Operating income | $27.06B | $59.62B | $31.74B | $23.68B | $33.45B | — | -54.6% |
| Net interest income | -$186.00M | $2.55B | $2.45B | $1.83B | $356.00M | — | -107.3% |
| Pre-tax income | $26.88B | $62.17B | $34.19B | $25.52B | $33.80B | — | -56.8% |
| Tax provision | $5.89B | $13.62B | $7.29B | $5.51B | $7.30B | — | -56.8% |
| Net income | $20.99B | $48.56B | $26.89B | $20.01B | $26.50B | — | -56.8% |
| Net income to common | $20.99B | $48.56B | $26.89B | $20.01B | $26.50B | — | -56.8% |
| Basic EPS | 4.74 | 10.93 | 6.06 | — | 5.96 | 6.54 | -56.6% |
| Diluted EPS | 4.74 | 10.91 | 6.04 | — | 5.96 | 6.53 | -56.6% |
| EBIT | $28.38B | $65.67B | $31.74B | $23.68B | $38.76B | — | -56.8% |
| EBITDA | $38.68B | $69.21B | $37.30B | $31.44B | $43.60B | — | -44.1% |
| Basic shares | 4.43B | 4.44B | 4.44B | — | 4.45B | 4.44B | -0.3% |
| Diluted shares | 4.44B | 4.45B | 4.45B | — | 4.45B | 4.45B | -0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $44.48B | $21.13B | $26.46B | $32.08B | $18.43B | +110.5% |
| Cash & short-term investments | $44.98B | $21.63B | $26.96B | $32.58B | $18.93B | +108.0% |
| Accounts receivable | $88.95B | $82.56B | $70.86B | $75.42B | $69.58B | +7.7% |
| Inventory | $51.35B | $51.35B | $49.62B | $47.50B | $45.65B | 0.0% |
| Total current assets | $208.70B | $177.32B | $172.45B | $181.88B | $162.71B | +17.7% |
| Property, plant & equipment | $231.76B | $219.97B | $208.38B | $193.24B | $180.76B | +5.4% |
| Goodwill & intangibles | $122.06B | $129.91B | $130.05B | $106.59B | $107.87B | -6.0% |
| Total assets | $594.94B | $559.22B | $542.90B | $512.29B | $482.15B | +6.4% |
| Total current liabilities | $239.08B | $225.16B | $215.66B | $234.36B | $207.52B | +6.2% |
| Current debt | $18.33B | $27.21B | $10.68B | $12.03B | $11.96B | -32.6% |
| Long-term debt | $121.79B | $119.17B | $111.70B | $89.18B | $87.31B | +2.2% |
| Total debt | $140.13B | $146.38B | $130.96B | $101.21B | $99.27B | -4.3% |
| Total liabilities | $373.66B | $356.16B | $348.86B | $342.39B | $314.09B | +4.9% |
| Retained earnings | $224.16B | $206.42B | $195.30B | $168.53B | $164.45B | +8.6% |
| Shareholder equity | $221.28B | $203.06B | $194.05B | $169.90B | $168.07B | +9.0% |
| Working capital | -$30.39B | -$47.84B | -$43.21B | -$52.48B | -$44.82B | +36.5% |
| Net tangible assets | $99.22B | $73.16B | $63.99B | $63.31B | $60.20B | +35.6% |
| Shares issued | 4.46B | 4.46B | 4.46B | 4.44B | 4.44B | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $20.99B | $48.56B | $26.89B | $20.01B | $26.50B | -56.8% |
| Depreciation & amortisation | $10.30B | $3.54B | $5.56B | $7.76B | $4.83B | +191.4% |
| Change in working capital | $13.32B | -$33.23B | $20.37B | -$9.16B | $7.94B | +140.1% |
| Operating cash flow | $55.20B | $24.08B | $7.62B | $44.98B | $41.77B | +129.2% |
| Capital expenditure | -$12.80B | -$12.04B | -$43.84B | -$15.41B | -$16.27B | -6.3% |
| Investing cash flow | -$12.76B | -$11.71B | -$42.81B | -$16.25B | -$14.12B | -9.0% |
| Share buybacks | -$3.50B | -$2.40B | $0 | $0 | $0 | -45.8% |
| Dividends paid | $0 | -$35.31B | $0 | -$16.66B | $174.00M | +100.0% |
| Financing cash flow | -$19.13B | -$17.43B | $29.47B | -$15.14B | -$47.35B | -9.7% |
| Free cash flow | $42.40B | $12.04B | -$36.22B | $29.56B | $25.50B | +252.0% |
| End cash position | $44.48B | $21.13B | $26.46B | $32.08B | $18.43B | +110.5% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
299.38
-0.99% from price
SMA 20
305.94
-3.11% from price
SMA 50
311.09
-4.72% from price
SMA 100
291.23
+1.78% from price
SMA 200
299.43
-1.00% from price
EMA 12
300.44
-1.34% from price
EMA 26
305.35
-2.92% from price
EMA 50
304.89
-2.78% from price
RSI (14)
42.3
Neutral
MACD (12,26,9)
-4.91
Hist -0.87
ATR (14)
9.72
3.28% of price
Realised vol 30D
34.6%
Annualised
Bollinger upper
331.64
20, 2σ
Bollinger lower
280.25
20, 2σ
50 / 200 cross
Golden
311.09 vs 299.43
Trend bias
Below 200
-1.00%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.58
Less volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
34.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-43.8%
Peak to trough
Max drawdown 5Y
-77.6%
Peak to trough
ATR 14
9.72
3.28% of price
Beta (reported)
0.21
5Y monthly, from filing
Dividends & splits
Forward rate$7.08 / yr
Forward yield1.04%
5-year avg yield1.58%
Payout ratio41.65%
Ex-dividend dateAug 18, 2023
Next pay date—
Last split2:1
Split dateSep 13, 2023
Headlines
Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery?
Insider Monkey · 8m ago
Dow Jones Futures Fall With Tariffs In Focus; Nvidia, Warsh Ahead
Investor's Business Daily · 11m ago
Syria says Israel talks addressed de-escalation, staying out of Israel-Turkey tensions
AFP · 15m ago
FIA Hails Success of Landmark INDYCAR Freedom 250 Grand Prix as Motorsport Takes Centre Stage in Washington D.C.
Business Wire · 18m ago
The next big oil trade may have nothing to do with oil stocks
TheStreet · 18m ago
First lady Melania Trump says she 'loved' racing as a child
USA TODAY · 19m ago
Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable?
Insider Monkey · 19m ago
Crowder College offering training courses in August, September
The Joplin Globe, Mo. · 20m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.